Immune checkpoints: A therapeutic target in triple negative breast cancer

Early clinical trials investigating monoclonal antibodies targeting the T-cell inhibitory receptor programmed cell death 1 (PD-1) and its ligand PD-L1 have shown efficacy in melanoma, non-small cell lung cancer and renal cell carcinoma. We recently demonstrated PD-L1 expression in 20% of triple nega...

Descripción completa

Detalles Bibliográficos
Autores principales: Chawla, Akhil, Philips, Anne V, Alatrash, Gheath, Mittendorf, Elizabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4022604/
https://www.ncbi.nlm.nih.gov/pubmed/24843833
http://dx.doi.org/10.4161/onci.28325
_version_ 1782316435616301056
author Chawla, Akhil
Philips, Anne V
Alatrash, Gheath
Mittendorf, Elizabeth
author_facet Chawla, Akhil
Philips, Anne V
Alatrash, Gheath
Mittendorf, Elizabeth
author_sort Chawla, Akhil
collection PubMed
description Early clinical trials investigating monoclonal antibodies targeting the T-cell inhibitory receptor programmed cell death 1 (PD-1) and its ligand PD-L1 have shown efficacy in melanoma, non-small cell lung cancer and renal cell carcinoma. We recently demonstrated PD-L1 expression in 20% of triple negative breast cancers suggesting that targeting the PD-1/PD-L1 immune checkpoint may be an effective treatment modality in patients with this disease.
format Online
Article
Text
id pubmed-4022604
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-40226042015-04-08 Immune checkpoints: A therapeutic target in triple negative breast cancer Chawla, Akhil Philips, Anne V Alatrash, Gheath Mittendorf, Elizabeth Oncoimmunology Author's View Early clinical trials investigating monoclonal antibodies targeting the T-cell inhibitory receptor programmed cell death 1 (PD-1) and its ligand PD-L1 have shown efficacy in melanoma, non-small cell lung cancer and renal cell carcinoma. We recently demonstrated PD-L1 expression in 20% of triple negative breast cancers suggesting that targeting the PD-1/PD-L1 immune checkpoint may be an effective treatment modality in patients with this disease. Landes Bioscience 2014-04-08 /pmc/articles/PMC4022604/ /pubmed/24843833 http://dx.doi.org/10.4161/onci.28325 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Chawla, Akhil
Philips, Anne V
Alatrash, Gheath
Mittendorf, Elizabeth
Immune checkpoints: A therapeutic target in triple negative breast cancer
title Immune checkpoints: A therapeutic target in triple negative breast cancer
title_full Immune checkpoints: A therapeutic target in triple negative breast cancer
title_fullStr Immune checkpoints: A therapeutic target in triple negative breast cancer
title_full_unstemmed Immune checkpoints: A therapeutic target in triple negative breast cancer
title_short Immune checkpoints: A therapeutic target in triple negative breast cancer
title_sort immune checkpoints: a therapeutic target in triple negative breast cancer
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4022604/
https://www.ncbi.nlm.nih.gov/pubmed/24843833
http://dx.doi.org/10.4161/onci.28325
work_keys_str_mv AT chawlaakhil immunecheckpointsatherapeutictargetintriplenegativebreastcancer
AT philipsannev immunecheckpointsatherapeutictargetintriplenegativebreastcancer
AT alatrashgheath immunecheckpointsatherapeutictargetintriplenegativebreastcancer
AT mittendorfelizabeth immunecheckpointsatherapeutictargetintriplenegativebreastcancer

Ejemplares similares